A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia
Phase of Trial: Phase II
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Tisagenlecleucel-T (Primary)
- Indications Acute lymphoblastic leukaemia; B cell lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms ELIANA
- Sponsors Novartis; Novartis Pharmaceuticals
- 24 Jul 2017 Planned End Date changed from 1 Jan 2023 to 3 Mar 2022.
- 24 Jul 2017 Planned primary completion date changed from 1 Jan 2023 to 15 Dec 2017.
- 24 Jul 2017 Status changed from active, no longer recruiting to recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History